326 related articles for article (PubMed ID: 22989163)
1. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Wilson PD; Hutchings A; Jeans A; Macdougall IC
J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
[TBL] [Abstract][Full Text] [Related]
2. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.
Calvet X; Gené E; ÀngelRuíz M; Figuerola A; Villoria A; Cucala M; Mearin F; Delgado S; Calleja JL
Technol Health Care; 2016; 24(1):111-20. PubMed ID: 26409561
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
Rognoni C; Ortalda V; Biasi C; Gambaro G
Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
[TBL] [Abstract][Full Text] [Related]
5. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
Romanet T; Bedouch P; Zaoui P
Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
[TBL] [Abstract][Full Text] [Related]
7. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
8. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
[TBL] [Abstract][Full Text] [Related]
9. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.
Loughnane F; Muduma G; Pollock RF
Adv Ther; 2020 Mar; 37(3):1218-1232. PubMed ID: 32030608
[TBL] [Abstract][Full Text] [Related]
10. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
[TBL] [Abstract][Full Text] [Related]
12. [Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease].
Minutolo R; Liberti ME; Garofalo C; Pacilio M; Sagliocchi A; Sguazzo A; Scarpati L; Sagliocca A; Santangelo S; Provenzano M; Savino M; Conte G; De Nicola L
G Ital Nefrol; 2015; 32(5):. PubMed ID: 26480261
[TBL] [Abstract][Full Text] [Related]
13. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre.
Tan MLN; Windscheif PM; Thornton G; Gaynor E; Rodrigues A; Howarth L
Eur J Pediatr; 2017 Oct; 176(10):1419-1423. PubMed ID: 28844092
[TBL] [Abstract][Full Text] [Related]
14. [Economic impact of ferric carboxymaltose in haemodialysis patients].
Aiello A; Berto P; Conti P; Panichi V; Rosati A
G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
[TBL] [Abstract][Full Text] [Related]
15. Budget Impact Analysis of Oral Fisiogen Ferro Forte
Darbà J; Ascanio M
Clin Drug Investig; 2018 Sep; 38(9):801-811. PubMed ID: 29934762
[TBL] [Abstract][Full Text] [Related]
16. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
[TBL] [Abstract][Full Text] [Related]
17. Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.
Riccio E; Sabbatini M; Capuano I; Pellegrino AM; Petruzzelli LA; Pisani A
BMC Nephrol; 2020 Feb; 21(1):57. PubMed ID: 32087684
[TBL] [Abstract][Full Text] [Related]
18. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.
Calvet X; Ruíz MÀ; Dosal A; Moreno L; López M; Figuerola A; Suarez D; Miquel M; Villoria A; Gené E
PLoS One; 2012; 7(9):e45604. PubMed ID: 23029129
[TBL] [Abstract][Full Text] [Related]
19. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
20. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]